Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients

Palbociclib is an oral CDK4/6 inhibitor indicated in HR+/HER2- advanced or metastatic breast cancer in combination with hormonotherapy. Its main toxicity is neutropenia. The aim of our study was to describe the kinetics of circulating neutrophils from real-life palbociclib-treated patients. A popula...

Full description

Bibliographic Details
Published in:Pharmaceutics
Main Authors: Alexandre Le Marouille, Emma Petit, Courèche Kaderbhaï, Isabelle Desmoulins, Audrey Hennequin, Didier Mayeur, Jean-David Fumet, Sylvain Ladoire, Zoé Tharin, Siavoshe Ayati, Silvia Ilie, Bernard Royer, Antonin Schmitt
Format: Article
Language:English
Published: MDPI AG 2021-10-01
Subjects:
palbociclib
neutropenia
pharmacokinetic/pharmacodynamic
Online Access:https://www.mdpi.com/1999-4923/13/10/1708

Internet

https://www.mdpi.com/1999-4923/13/10/1708

Similar Items